View Item 

Show simple item record

Issues in selecting HCV‐infected candidates for anti‐viral treatment
dc.contributor.authorLok, Anna S.en_US
dc.date.accessioned2012-05-21T15:49:38Z
dc.date.available2013-06-11T19:15:53Zen_US
dc.date.issued2012-04en_US
dc.identifier.citationLok, Anna S. (2012). "Issues in selecting HCV‐infected candidates for anti‐viral treatment ." Clinical Liver Disease 1(2): 29-31. <http://hdl.handle.net/2027.42/91215>en_US
dc.identifier.issn2046-2484en_US
dc.identifier.issn2046-2484en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/91215
dc.description.abstractWatch the interview with the authors Answer questions and earn CMEen_US
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.titleIssues in selecting HCV‐infected candidates for anti‐viral treatmenten_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGastroenterologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumFrom the University of Michigan Health System, Ann Arbor, MIen_US
dc.contributor.affiliationumUniversity of Michigan Medical Center, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/91215/1/18_ftp.pdf
dc.identifier.doi10.1002/cld.18en_US
dc.identifier.sourceClinical Liver Diseaseen_US
dc.identifier.citedreferenceSarazzin C, Kieffer TL, Bartels D, Hanzeika B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767 ‐ 1777.en_US
dc.identifier.citedreferenceZeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417 ‐ 2428.en_US
dc.identifier.citedreferencePoordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski M, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy [abstract]. J Hepatol 2011; 54: S6.en_US
dc.identifier.citedreferenceJacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda A, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol 2011; 54: S542.en_US
dc.identifier.citedreferenceGe D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009; 461: 399 ‐ 401.en_US
dc.identifier.citedreferencePoordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195 ‐ 1206.en_US
dc.identifier.citedreferenceJacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405 ‐ 2416.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
18_ftp.pdf
Size:
973.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.